Oxytocin and Naltrexone successfully treat hypothalamic obesity in a boy post-craniopharyngioma resection.

Oxytocin and Naltrexone successfully treat hypothalamic obesity in a boy post-craniopharyngioma resection.

J Clin Endocrinol Metab. 2017 Dec 06;:

Authors: Hsu EA, Miller JL, Perez FA, Roth CL

Abstract
Context: Hypothalamic obesity, a treatment-resistant condition common to survivors of craniopharyngioma (CP), is strongly associated with a poor quality of life in this population. Oxytocin (OT), a hypothalamic neuropeptide, has been shown to play a role in the regulation of energy balance and to have anorexigenic effects in animal studies. Naltrexone (NAL), an opiate antagonist, has been shown to deter hedonic eating and to potentiate OT's effects.
Case description: In this parent-observed study, we tested the administration of intranasal OT for 10 weeks (phase 1), followed by a combination of intranasal OT and NAL for 38 weeks (phase 2) in a 13-year-old male with confirmed hypothalamic obesity and hyperphagia post-CP resection. Treatment resulted in: (1) reduction in BMI z-score from 1.77 to 1.49 over 10 weeks during phase 1; (2) reduction in BMI z-score from 1.49 to 0.82 over 38 weeks during phase 2; (3) reduced hyperphagia during phases 1 and 2; (4) continued hedonic high-carbohydrate food seeking in the absence of hunger during phases 1 and 2; and (5) sustained weight reduction during decreased parental monitoring and free access to unlocked food in the home during the last 10 weeks of phase 2.
Conclusion: This successful intervention of CP-related hypothalamic obesity and hyperphagia by OT alone and in combination with NAL is promising for conducting future studies of this treatment-recalcitrant form of obesity.

PMID: 29220529 [PubMed - as supplied by publisher]

http://ift.tt/2AGhkSy